Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

236.67USD
11:57pm IST
Change (% chg)

$2.68 (+1.15%)
Prev Close
$233.99
Open
$234.13
Day's High
$237.17
Day's Low
$233.00
Volume
228,663
Avg. Vol
1,076,879
52-wk High
$282.57
52-wk Low
$184.58

AGN.N

Chart for AGN.N

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.12
Market Cap(Mil.): $78,439.23
Shares Outstanding(Mil.): 335.22
Dividend: 0.70
Yield (%): 1.20

Financials

  AGN.N Industry Sector
P/E (TTM): -- 28.87 29.67
EPS (TTM): -3.12 -- --
ROI: -0.75 13.62 13.13
ROE: -1.71 14.52 14.27

BRIEF-Allergan reports availability of restasis multidose

* Allergan announces availability of restasis multidose™ (cyclosporine ophthalmic emulsion) 0.05 pct -- the first fda-approved preservative free prescription eye drop available in a multidose bottle

22 Mar 2017

BRIEF-Juvéderm Vollure XC approved by FDA for correction of facial wrinkles and folds

* Juvéderm Vollure™ XC approved by U.S. FDA for correction of facial wrinkles and folds in adults over the age of 21

20 Mar 2017

Allergan signs deal with Editas for gene-editing-based eye treatments

Allergan plc said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine Inc's experimental gene-editing-based eye treatments under a research and development deal between the two companies.

14 Mar 2017

UPDATE 1-Allergan signs deal with Editas for gene-editing-based eye treatments

March 14 Allergan plc said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine Inc's experimental gene-editing-based eye treatments under a research and development deal between the two companies.

14 Mar 2017

Allergan signs deal with Editas for gene-editing-based eye treatments

March 14 Allergan plc said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine Inc's experimental gene-editing-based eye treatments under a research and development deal between the two companies.

14 Mar 2017

BRIEF-Allergan and Editas Medicine enter into strategic research and development alliance

* Allergan and Editas Medicine enter into strategic research and development alliance to discover and develop Crispr Genome editing medicines for eye diseases

14 Mar 2017

BRIEF-Cisco appoints Brenton Saunders, CEO Of Allergan Plc, to board of directors

* Cisco appoints brenton l. Saunders, chairman, president and ceo of allergan plc, to board of directors Source text for Eikon: Further company coverage:

14 Mar 2017

BRIEF-Supernus announces settlement with Actavis on Trokendi XR patent litigation

* Supernus announces settlement with Actavis on Trokendi XR patent litigation

07 Mar 2017

BRIEF-Zeltiq Aesthetics posts Q4 profit of $0.25/share

* Zeltiq announces fourth quarter and full year 2016 financial results

02 Mar 2017

BRIEF-Orexo files patent infringement lawsuit against Actavis

* Orexo commences patent infringement litigation against Actavis for their generic versions of Suboxone® and Subutex® tablets in the U.S.

01 Mar 2017

More From Around the Web

Earnings vs. Estimates